Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.
Latest update： 18/11/2019 15:59:59
Oita University Institute of Advanced Medicine, Inc.
We are challenging the development of new small-molecule drugs using peptide mimetics technology!
Using our unique drug development technology targeting “protein interacting interfaces,” we reinvent “small-molecule drugs” and strive to meet unmet needs including intracellular needs that could not be met by “antibody drugs” and “non-standard peptide drugs”, thus contributing to the development and dissemination of effective and reasonable medical treatment.
- Peptide mimetics technology that allows development of small-molecule drugs targeting “protein interacting interfaces”
Our unique peptide mimetics technology
This technology designs low-molecular compounds that selectively inhibit “protein interacting interfaces” affecting the occurrence of diseases in human cells so that they are suited for three-dimensional structures of target proteins. • This technology contributes to the shortening of development periods for new pharmaceuticals by significantly reducing the time and costs required to find compounds that can be candidate substances for new pharmaceuticals. • We can conduct a joint research project with a pharmaceutical company or research institute and grant a license to a pharmaceutical company if a prospective compound for new pharmaceuticals is found.